Study Evaluating LXR-623 in Healthy Subjects

To evaluate the safety and tolerability of a single dose of LXR-623 in healthy subjects.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Healthy

Age range

19 year–50 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Lincoln, Nebraska, 68502, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion:

Healthy, men or women, aged 19-50 years

Exlcusion:

Use of any investigational or prescription drug within 30 days before study start
Any clinically imprtant medical disease or abnormal laboratory test results

Treatment and study plan

LXR-623

Drug

Primary outcomes

Safety and Tolerability

Sponsors and collaborators

Lead sponsor

Wyeth is now a wholly owned subsidiary of Pfizer

Industry

Registry information

Official study title

Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of LXR-623 Administered Orally to Healthy Subjects

Important dates

Study start: 2006
Primary completion: 2006
Study completion: 2006
First posted: Aug 21, 2006
Registry last updated: Aug 7, 2009

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed